Table 1. Characteristics of patients who... | American Society of Hematology

Table 1.

Characteristics of patients who developed EBV-related complications

Pt no.	Diagnosis	Preparative regimen	Age, y	CMV status	Time to EBV event, d	EBV event	Method of diagnosis	Treatment	GVHD prophylaxis regimen	Time to acute GVHD grade II-IV, d	Outcome/cause of death
1	MDS	NMA with ATG	58	+	247	PTLD	Colon biopsy	Rituximab	CsA/MMF	50	Alive
2	AML	NMA with ATG	60	–	133	PTLD	Tonsil biopsy	Rituximab	CsA/MMF	35	Alive
3	SAA	NMA with ATG	35	–	122	PTLD	Multiple biopsies^*	Rituximab	CsA/MMF	None	Dead/PTLD
4	CML	NMA with ATG	48	+	185	PTLD	Multiple biopsies†	Rituximab	CsA/MMF	24	Dead/PTLD
5	CLL	NMA with ATG	50	–	54	PTLD	PCR	Rituximab	CsA/MMF	None	Alive
6	SAA	NMA with ATG	18	+	117	Viremia	PCR	None	CsA/MMF	None	Alive
7	AML	NMA	49	–	603	PTLD	Autopsy	None	CsA/MMF	30	Dead/hemophagocytic syndrome
8	CML	MA with ATG	49	–	133	PTLD	LND biopsy	Rituximab vincristine	CsA/M-pred	None	Dead/PTLD
9	MDS	MA with ATG	49	–	131	PTLD	Stomach biopsy	Rituximab	CsA/M-pred	72	Alive
10	AML	MA with ATG	7	–	407	PTLD	Autopsy	None	CsA/M-pred	38	Dead/alveolar hemorrhage and PTLD
11	ALL	MA with ATG	14	+	112	Viremia	PCR	None	CsA/M-pred	16	Dead/MOF and sepsis
12	CML	MA with ATG	17	–	52	Viremia	PCR	None	CsA/M-pred	36	Alive
13	ALD	MA with ATG	8	–	93	PTLD	PCR CT scan	Rituximab	CsA/M-pred	None	Alive
14	OP	MA with ATG	4	–	61	Viremia	PCR	None	CsA/MMF	15	Dead/GVHD
15	MLS	MA with ATG	7	–	92	PTLD	Liver biopsy	Rituximab methypred	CsA/M-pred	None	Dead/PTLD

Pt no.	Diagnosis	Preparative regimen	Age, y	CMV status	Time to EBV event, d	EBV event	Method of diagnosis	Treatment	GVHD prophylaxis regimen	Time to acute GVHD grade II-IV, d	Outcome/cause of death
1	MDS	NMA with ATG	58	+	247	PTLD	Colon biopsy	Rituximab	CsA/MMF	50	Alive
2	AML	NMA with ATG	60	–	133	PTLD	Tonsil biopsy	Rituximab	CsA/MMF	35	Alive
3	SAA	NMA with ATG	35	–	122	PTLD	Multiple biopsies^*	Rituximab	CsA/MMF	None	Dead/PTLD
4	CML	NMA with ATG	48	+	185	PTLD	Multiple biopsies†	Rituximab	CsA/MMF	24	Dead/PTLD
5	CLL	NMA with ATG	50	–	54	PTLD	PCR	Rituximab	CsA/MMF	None	Alive
6	SAA	NMA with ATG	18	+	117	Viremia	PCR	None	CsA/MMF	None	Alive
7	AML	NMA	49	–	603	PTLD	Autopsy	None	CsA/MMF	30	Dead/hemophagocytic syndrome
8	CML	MA with ATG	49	–	133	PTLD	LND biopsy	Rituximab vincristine	CsA/M-pred	None	Dead/PTLD
9	MDS	MA with ATG	49	–	131	PTLD	Stomach biopsy	Rituximab	CsA/M-pred	72	Alive
10	AML	MA with ATG	7	–	407	PTLD	Autopsy	None	CsA/M-pred	38	Dead/alveolar hemorrhage and PTLD
11	ALL	MA with ATG	14	+	112	Viremia	PCR	None	CsA/M-pred	16	Dead/MOF and sepsis
12	CML	MA with ATG	17	–	52	Viremia	PCR	None	CsA/M-pred	36	Alive
13	ALD	MA with ATG	8	–	93	PTLD	PCR CT scan	Rituximab	CsA/M-pred	None	Alive
14	OP	MA with ATG	4	–	61	Viremia	PCR	None	CsA/MMF	15	Dead/GVHD
15	MLS	MA with ATG	7	–	92	PTLD	Liver biopsy	Rituximab methypred	CsA/M-pred	None	Dead/PTLD

Pt indicates patient; CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome; NMA, nonmyeloablative; ATG, antithymocyte globulin; PTLD, posttransplantation lymphoproliferative disorder; CsA, cyclosporine A; AML, acute myeloid leukemia; SAA, severe aplastic anemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; PCR, polymerase chain reaction; MA, myeloablative; LND, lymph node; M-pred, Methylprednisolone; MOF, multiple organ failure; ALD, adrenoleukodystrophy; CT scan, computerized tomography; OP, osteopetrosis; and MLS, Maroteaux-Lamy syndrome

Liver, marrow, and skin biopsies

†

Liver, tonsil, and lung biopsies

View Large

This Feature Is Available To Subscribers Only